Human immunodeficiency virus type-1 (HIV-1) chronic infection causes millions of deaths each year. We previously developed a novel HIV-1 Gag-spe cific exosome (EXO)-targeted T cell-based vaccine (Gag-Texo) using ConAstimulated polyclonal CD8 + T (ConA-T) cells armed with Gag-specific dendritic cell (DC)-released EXOs, and showed that Gag-Texo stimulated more efficient cytotoxic T lymphocyte (CTL) responses than DCs. Tat HIV-1 early regulatory protein possesses immunomodulatory and adjuvant properties. To enhance Gag-Texo immunogenicity, we generated Tat-engineered OVA/Tat Texo and Gag/Tat-Texo vaccines using ConA-T cells armed with EXOs release by DCs infected with recombinant OVA/Tat-and Gag/Tat-expressing adenoviruses (AdV OVA/Tat and AdV Gag/Tat ). We then assessed vaccination-stimulated CTL responses in naïve mice, and therapeutic immunity in transgenic HLA-A2 mice bearing Gag/HLA-A2-expressing BL6-10 OVA/A2 melanoma lung metastases. We demonstrate that the OVA/Tat-Texo vaccine enhances functional OVA-specific CTL responses, compared to the OVA-Texo vaccine, and broadens CTL responses recognizing the cryptic OVA epitope in C57BL/6 mice. Furthermore, we determine that the Gag/Tat-Texo not only stimulates more efficient CTL responses than Gag-Texo, but also induces enhanced therapeutic immunity. We show that, 30% of Gag/Tat-Texo-immunized mice are free of tumor lung-metastases, compared to all Gag-Texo-immunized mice displaying lung-metastasis. In addition, the average number of tumor lung metastases colonies (32/lung) in the Gag/Tat-Texo-immunized mice was also 
Introduction
HIV-1 that causes millions of deaths each year primarily acts by infecting memory CD4 + CCR5 + T cells, and becomes resistant to antiviral drug therapy (ART).
This results in latent pro-viral reservoirs and a life-long infection [1] . As wellestablished in natural control of HIV-1 (i.e. "elite" control), potent CTLs can control it by killing virus-infected cells [2] , leading to renewed interests in therapeutic vaccination for stimulating CTL responses decaying pro-viral reservoirs after pharmacologically purging the reservoirs [3] . Purging the reservoir itself is not sufficient to cause death of infected cells that remain in a resting state [4] , whereas boosting CTL responses efficiently eliminates latent pro-viral reservoirs [4] [5], warranting a search for potent therapeutic vaccines. Structural proteins of HIV-1, Gp120 and Gag, have become major targets for inducing HIV-1-specific CTL responses in vaccine development [6] [7] . Previous vaccines (peptides, DNA or viral vectors) often failed in stimulation of therapeutic immunity in HIV-1 patients [8] possibly due to critical defects in CD4 + T cells and DCs [1] . Immune cell-based treatment approaches become a third pillar of therapeutics [8] . However, efficacies of DC vaccinations, which often require CD4 + T cell help [9] remain poor [10] . Functional CTL exhaustion becomes another chief issue, leading to ineffective HIV-1 control in patients [11] [12]. We previously generated an HIV-1 Gp120-specific exosome (EXO)-targeted Gp120-Texo vaccine by using ConA-T-stimulated mousepolyclonal T cells armed with Gp120-specific DC (DC Gp120 )-released EXO (EXO Gp120 ) [13] [14] . We demonstrated that the Gp120-Texo vaccine was more immunogenic than the DC Gp120 vaccine and was capable of stimulating CD4 + T cell-independent Gp120-specific CTL responses, leading to protective and long-term immunity against Gp120/HLA-A2-expressing B16 melanoma (BL6-10 Gp120/A2 ) in transgenic HLA-A2 mice [13] [14] . Compared to the HIV-1 structural protein Gp120, HIV-1 Gag has several important advantages as a target antigen for developing HIV-1-specific vaccines. Thus, the Gag vaccine stimulates persistent and broader CTL responses against conserved Gag epitopes in animal models [15] [21] . Since Gag has become one of the most attractive target candidates for HIV-1 vaccine development, we recently generated a Gag-specific DC (DC Gag )-released EXO-targeted Gag-Texo vaccine, and demonstrated that Gag-Texo stimulated efficient Gagspecific CTL responses, leading to a complete protective immunity, but only some degree of therapeutic immunity against Gag/HLA-A2-expressing BL6-10 Gag/A2 melanoma in transgenic HLA-A2 mice [22] . Like other lentiviruses, HIV-1 encodes a trans-activating regulatory protein (Tat), which is essential for efficient transcription of the viral genome [23] . Since the HIV-1 early regulatory protein Tat possesses immunomodulatory and adjuvant properties that can be advantageous in vaccine development [23] , we assumed that Tat may further enhance the immunogenicity of our Gag-Texo vaccine.
To assess our assumption, we produced recombinant adenoviruses AdV OVA/Tat and AdV Gag/Tat expressing OVA plus Tat and Gag plus Tat, and generated OVA/ 
Dendritic Cell and Exosome Preparations
Bone marrow-derived dendritic cells (DCs) were obtained by culturing the wildtype B6 or transgenic HLA-A2 mousebone marrow cells in culture medium containing GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) for six days as previously described [22] . DCs derived from B6 and HLA-A2 mice were infected with AdV OVA 
OVA/Tat-Texo and Gag/Tat-Texo Preparations
The wild-type B6 or transgenicHLA-A2 mouse splenocytes were cultured in RPMI1640 medium containing IL-2 (20 U/ml) and ConA (1 μg/ml) for 3 days.
ConA-activated CD8 + T (ConA-T) cells were enriched by passage through nylon wool columns (C & A Scientific, Manassas, VA), and then purified by negative selection using anti-mouse CD8 paramagnetic beads (DYNAL Inc., Lake Success, NY). OVA-Texo or OVA/Tat-Texo and Gag-Texo or Gag/Tat-Texo vaccines were generated by incubation of ConA (1 µg/ml)-stimulated polyclonal CD8 + T (ConA-T) cells derived from B6 and HLA-A2 mice with EXO OVA or EXO OVA/Tat and EXO Gag or EXO Gag/Tat for two hours, respectively, as previously described [13] .
Electron Microscopic Analysis
EXOs were fixed in 4% paraformaldehyde. The pellets were then loaded onto carbon-coated formvar grids. The EXO sample-loaded grids were stained with saturated aqueous uranyl, and then examined with a JEOL 1200EX electron microscope at 60 kV.
Western Blot Analysis
Cell lysates (10 µg/well) were loaded onto 12% acrylamide gels, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and subsequently transferred onto nitrocellulose membranes (Millipore, Bedford, MA).
Membranes were blocked with ODYSSEY blocking buffer (LI-COR Bioscience, Lincoln, NE), immunoblotted with anti-gagAb, incubated withanti-goat IRDyeR800CW Ab, and then scanned using ODYSSEY instrument according to manufacturer's instruction (LI-COR Bioscience).
Flow Cytometric Analysis
DCs were stained with a panel of Abs and analyzed by flow cytometry [13] . 
Cytotoxicity Assay
The in vivo cytotoxicity assay was performed as previously described [22] . 
Animal Studies
To examine the therapeutic antitumor immunity conferred by Gag/Tat-Texo vaccine, the transgenic HLA-A2 mice (10 mice per group) were first injected i.v.
with 0.5 × 10 6 BL6-10 Gag/A2 cells. Six days after tumor cell inoculation, HLA-A2 mice were injected i.v. with Gag/Tat-Texo or Gag-Texo (2 × 10 6 cells/mouse).
The mice were sacrificed 3 weeks after tumor cell injection, and metastatic tumor colonies were counted in lungs in a blind fashion. Metastases on freshly isolated lungs appeared as discrete black pigmented foci that were easily distinguishable from normal lung tissues and confirmed by histological examination.
Metastatic foci too numerous to count were assigned an arbitrary value of >300.
Statistic Analyses
Statistical analyses were performed using the Student t test for comparison of variables from different groups. A value of p < 0.05 was considered to be statistically significant.
Results

Generation of the Transgene Tat-Engineered OVA/Tat-Texo Vaccine
We used a recombinant DNA technology to construct a recombinant OVA and (Figure 2(b) ). Following this assessment, we then purified EXOs from cell culture supernatants of DC OVA and DC OVA/Tat by differential ultracentrifugation, as previously described [13] . We demonstrated by electron microscopy that EXOs had a typical exosomal characteristic of "saucer" or round shape with a diameter between 50 -90 nm (Figure 2(c) ), and Western blotting revealed expression of EXO marker CD9 [27] (Figure 2(d) ).
We then generated the OVA-Texo and OVA/Tat-Texo vaccines using ConAstimulated B6 polyclonal CD8 + T (ConA-T) cells armed with DC OVA -or DC OVA/Tat -released EXOs, respectively, by incubating ConA-T cells with EXOs for 2 hours, as previously described [13] . Tat 
The Transgene
Generation of the Transgene Tat-Engineered Gag/Tat-Texo Vaccine
We also constructed recombinant Gag and Tat (Gag/Tat)-expressing adenovirus (AdV Gag/Tat ) by using recombinant DNA technology (Figure 1 ). We infected transgenic HLA-A2 mouse bone marrow-derived DCs with AdV Gag and AdV Gag/Tat , and generated DC Gag and DC Gag/Tat . We showed that DC Gag/Tat expressed cell surface DC marker CD11c, HLA-A2 and DC maturation markers (Figure 4(c) ). Next, we assessed the ability of Gag/Tat-Texo to induce the differentiation of stimulated CD8 + T-cells into effector CTLs. We adoptively transferred Gag 76-84 peptide-pulsed splenocytes that had been strongly labeled with CSFE (CFSE high ), as well as the control HER2 peptide-pulsed splenocytes that had been weakly labeled with CFSE (CFSE low ) at 1:1 ratio, into recipient mice that had been pre-vaccinated with either Gag/Tat-Texo or Gag-Texo.
The transfer was performed at day seven following the vaccinations. Sixteen hours after the cell transfer, mouse splenocytes were analyzed by flow cytometry.
We found that there was substantial loss (53% and 68%) of the CFSE high cells in the Gag/Tat-Texo-and Gag-Texo-immunized HLA-A2 mice (Figure 4 
The Transgene Tat-Engineered Gag/Tat-Texo Vaccine Enhances Gag-Specific Therapeutic Immunity in Tumor-Bearing Transgenic Mice
To assess a potential therapeutic effect of Gag/Tat-Texo, we first challenged HLA-A2 mice with BL6-10 Gag/A2 melanoma cells expressing cell surface HLA-A2 and cytoplasmic Gag [22] . Six days after tumor cell challenge, mice were immunized with Gag/Tat-Texo, Gag-Texo or PBS, respectively. Three weeks after tumour challenge, we found that, three out of ten (3/10) Gag/Tat-Texo-immunized mice were free of metastatic tumors in lungs, in contrast to Gag-Texo-immunized mice that all (10/10) carried lung tumor metastasis (Figure 4(e) ). In addition, an average number (32/lung) of lung tumor colonies in seven Gag/ Tat-Texo-immunized micewas also significantly lower than that (78/lung) in Gag-Texo-immunized mice (Figure 4 (e)), indicating that the Gag/Tat-Texo vaccine induces more efficient therapeutic immunity than Gag-Texo without Tat expression. We recently demonstrated that the OVA-Texo vaccine directly converted CTL exhaustion independent of the host CD4 + T cell help via its CD40L signaling activation of the mTORC1 pathway, and the Gag-Texo vaccine stimulated Gagspecific therapeutic immunity against Gag-expressing BL6-10 Gag melanoma lung metastases in AdV OVA -induced chronic infection [43] . In this study, we provide the first evidence that Tat enhances CTL responses and therapeutic immunity in T cell-based vaccines. We demonstrate that the transgene Tat-engineered OVA/ Tat-Texo vaccine not only enhances OVA-specific CTL responses, but also broadens their recognition to the cryptic OVA epitope. This is further supported by the evidence that Tat also enhances Gag-specific CTL responses derived from the Gag/Tat-Texo vaccination, suggesting that Gag/Tat-Texo-stimulate Gagspecific CTL responses may also eradicate HIV-1-infected cells if the vaccine is applied to HIV-1 patients. Importantly, the Gag/Tat-Texo vaccine further stimulates more efficient therapeutic immunity than Gag-Texo in transgenic HLA-A2 mice bearing 6 day-established HLA-A2/Gag-expressing BL6-10 Gag/A2 melanoma lung metastases. We thus, assume that our transgene Tat-engineered EXO-targeted T cell-based vaccine might more efficiently convert CTL res-ponses and stimulate Gag-specific therapeutic immunity in chronic infection. To assess our assumption, similar vaccination experiments using the OVA/TatTexo and Gag/Tat-Texo vaccines, are underway in our laboratory in our recently described chronic infection model [43] .
Discussion
Conclusion
Our novel transgene Tat-engineered Gag/Tat-Texo vaccine capable of directly stimulating efficient Gag-specific CTL responses and potent therapeutic immunity in transgenic HLA-A2 mice may be useful as a new immunotherapeutic vaccine for controlling virus in HIV-1 patients with CD4 + T cell deficiency, who are being subjected to the antiviral drug therapy.
